Study to Evaluate Efficacy of EnXtra on Accuracy & Reaction Time, Perceived Alertness & Digital Fatigue for Video Gamers
NCT ID: NCT05586880
Last Updated: 2023-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-10-10
2023-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effect of EnXtra® and EnXtra® + Caffeine on Mental Alertness and Fatigue in Healthy Individuals
NCT06560008
A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults
NCT03731286
A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue
NCT02816827
Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study
NCT04234529
Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
NCT03186027
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EnXtra 300 mg/ capsule
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Experimental: EnXtra 300 mg/ capsule
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Microcrystalline cellulose (MCC) 300mg
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Microcrystalline cellulose (MCC) 300mg
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental: EnXtra 300 mg/ capsule
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Microcrystalline cellulose (MCC) 300mg
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects with Body Mass Index (BMI) 18 - 29.9 kg/ m2
3. Subjects with history of playing video games for 6 or more hours/ week for 6 months before the screening
4. Subject who can read and understand English language with ease.
5. Fasting blood glucose (FBG) ≤ 125 mg/dl
6. Subjects with history of regular sleep and agree to sleep for 8 ±1 hours the night before the visit day.
7. Subjects who agree to maintain their usual dietary habits and level of exercise i.e. maintain their usual life-style throughout the trial period.
8. Subjects willing to refrain from consuming alcohol 24 hours prior to the visit days.
9. Subjects willing to refrain from consuming caffeine and caffeine-containing products 24 hour prior to visit days.
10. Willing to participate in the study with a signed and dated written consent.
Exclusion Criteria
2. Subjects suffering from chronic fatigue, stress or anxiety.
3. Subjects with uncontrolled hypertension with systolic blood pressure ≥130 and diastolic blood pressure ≥89 mm Hg.
4. Subjects with uncontrolled Type II Diabetes Mellitus with FBG \>125 mg/ dl
5. Subjects with Hemoglobin (Hb) ≤ and/or ≥ 13.5 - 17.0 g/Dl inmales and 12.0 - 15.0 g/dL in females.
6. Subjects with ≤ and/or ≥ Total Leucocyte Counts (TLC) 4.0 - 10.0 x 10 3/U
7. Subjects with Differential Leukocyte Counts (DLC) outside the normal range. \[Neutrophils: 40 - 80 %, Lymphocytes: 20 - 40 %, Monocytes: 2 - 10 %, Eosinophils: 1 - 6 %, Basophils: 0 - 0.02 %\]
8. Subjects with AST values ≤ and/or ≥ 40 U/L in males and 32 U/Lin females.
9. Subjects with ALT values ≤ and/or ≥ 41 U/L in males and 33 U/Lin females
10. Subjects with Creatinine ≤ and/or ≥ Males: 59-104 μmol/L in males and 45-84 μmol/L in females
11. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders.
12. Chronic Alcoholics and smokers
13. Subjects taking any medications or preparations to improve gaming performance (herbal, dietary supplements, homeopathic preparations, etc.) and/or cognitive performance during the study.
14. Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator may interfere with evaluations in the study or noncompliance with treatment or visits.
15. Subjects who are on anxiolytics, anti-depressants, antipsychotics, anticonvulsants, antihypertensive, centrally acting corticosteroids, opioid pain relievers, hypnotics, and/or prescribed sleep medications.
16. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
17. Subjects who have had participated in a study of an investigational product 90 days prior to the screening.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Shalini Srivastava, MD medicine
Role: PRINCIPAL_INVESTIGATOR
Vedic Lifesciences Pvt. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr D Y Patil medical college
Nerul, Maharashtra, India
Dr. Sarala Kataria Clinic
Thāne, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OM/220502/ENXTRA/RTPADF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.